APRI (Aprinoia Therapeutics) Total Debt per Share: $0.71 (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics Total Debt per Share?

Aprinoia Therapeutics APRI Total Debt per Share is $0.71 as of Dec. 2023.

$0.71 (As of Dec. 2023)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Aprinoia Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2023 was $0.71.

Aprinoia Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Total Debt per Share Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Debt per Share
0.04 0.10 0.68

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Total Debt per Share 0.04 0.00 0.10 0.56 0.71

Aprinoia Therapeutics Total Debt per Share Calculation

Aprinoia Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.21+18.78)/27.94
=0.68

Aprinoia Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.21+18.78)/26.86
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.71 mean?
Aprinoia Therapeutics (APRI) has a Total Debt per Share of $0.71 as of Dec. 2023. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Total Debt per Share too high?
Aprinoia Therapeutics' current Total Debt per Share is $0.71.
How does Aprinoia Therapeutics' Total Debt per Share compare to ?
Aprinoia Therapeutics' Total Debt per Share of $0.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Total Debt per Share is $0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Total Debt per Share of $0.71. The current Total Debt per Share is $0.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Total Debt per Share is $0.71 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.